Vorasidenib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Vorasidenib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
29
Registered trials
26
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Vorasidenib can convert its Small molecule drug profile and IDH1 x IDH2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Vorasidenib (query alias: vorasidenib) |
|---|---|
| Modality / target | Small molecule drug; IDH1 x IDH2; IDH1 inhibitors, IDH2 inhibitors, Epigenetic drug |
| Highest global status | Approved |
| Originator | Celgene Corp. |
| Active developers | Institut de Recherches Internationales Servier, Institut de Recherches Intern Servier, Servier Laboratories (Australia) Pty Ltd. |
The MCP disease footprint includes Oligodendroglioma, IDH2 mutant Glioma, Astrocytoma, IDH-Mutant. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07629089 | Phase 1 | Not yet recruiting | 24 | Recommended Combination Dose (RCD) |
| NCT07547163 | Not Applicable | Recruiting | 90 | Characterize and compare the experience of patients with IDH-mutant, grade 2 gliomas |
| CTR20254821 | Not Applicable | 进行中 （招募完成） | 68 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Real-world assessment of treatment adherence among vorasidenib-treated patients with IDH-mutant glioma.
Not Applicable; n=186; evaluation: Positive. Reported fields: MPR(3-month) = 0.89 Mean MPR ; MPR(3-month) = 0.92 Mean MPR ; MPR(3-month) = 0.92 Mean MPR
Impact of vorasidenib vs placebo on seizure rates and quality of life: Exploratory analysis from the phase 3 INDIGO study.
Phase 3; n=110; evaluation: Positive. Reported fields: Rate of on-treatment seizures per person-year = 64.9 per person-year ( 26.5 - 159.1); Rate of on-treatment seizures per person-year = 13.2 per person-year ( 5.8 - 29.8)
Comparative response assessment using PET-RANO 1.0 and RANO 2.0 in vorasidenib-treated IDH-mutant gliomas: The VORAFET study.
Not Applicable; n=26; evaluation: Positive. Reported fields: PD = 5.3 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Vorasidenib addresses Oligodendroglioma, IDH2 mutant Glioma, Astrocytoma, IDH-Mutant. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-05-28 | Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million | Phase 3 | US$905.0M upfront |
| 2020-12-21 | Servier to Acquire Agios Pharmaceuticals' Oncology Business | Phase 1 | US$1,800.0M upfront; US$200.0M milestones; US$2,000.0M stated total |
| 2010-04-15 | Celgene Corporation and Agios Pharmaceuticals Announce Global Strategic Collaboration to Advance Unique Science of Cancer Metabolism | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
